Biosynex SA (EPA:ALBIO)

Market Cap	16.33M -30.3%
Revenue (ttm)	95.19M -5.9%
Net Income	-58.22M
EPS	-3.16
Shares Out	18.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,055
Open	0.8920
Previous Close	0.8920
Day's Range	0.8860 - 0.8940
52-Week Range	0.4550 - 1.5700
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products, as well as anti-mosquito bracelets and waterproof, moisturizi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Employees: 397
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2025, Biosynex's revenue was 95.19 million, a decrease of -5.90% compared to the previous year's 101.17 million. Losses were -58.22 million, 34.4% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 10, 2026

Data Sources Report a data error